Nektar Therapeutics NKTR announced today that positive data from the first single-ascending dose
Phase 1a clinical study of NKTR-192, the company's novel short-acting
mu-opioid analgesic candidate, demonstrate that the drug candidate achieved
its target pharmacokinetic profile. These data support its continued
development as a new analgesic for the treatment of acute pain. The company
also announced that dosing has commenced in a second single-ascending dose
Phase 1a clinical study of NKTR-192, which will explore the pharmacodynamic
profile of this new drug candidate in healthy subjects.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in